R&D channel feed

Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: #ESC23

Last year

Novo­cure fails PhI­II in plat­inum-re­sis­tant ovar­i­an can­cer

Last year

No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

Last year

Up­dat­ed: Bridge­Bio's AT­TR-CM drug bests place­bo in de­tailed PhI­II da­ta, bol­ster­ing plans for NDA

Last year

Blue­Rock, Bay­er's stem cell group, de­tails glimpses of ef­fi­ca­cy in Parkin­son's dis­ease ther­a­py

Last year

Mer­ck and Ei­sai to stop Keytru­da plus Lenvi­ma tri­al in head and neck can­cer af­ter dis­ap­point­ing in­ter­im re­sults

Last year

Once again, Novo's semaglu­tide shows car­dio­vas­cu­lar ben­e­fit, weight loss — this time in adults with heart fail­ure

Last year

Af­ter first-line ap­proval in DL­B­CL, de­bate con­tin­ues around ben­e­fit from Roche's ADC Po­livy

Last year

Ab­b­Vie drops two ear­ly-stage AD­Cs, in­clud­ing Pfiz­er-part­nered on­col­o­gy pro­gram

Last year
Pharma

KRAS late­com­er Roche draws cau­tious com­par­isons to Am­gen, Mi­rati in ear­ly da­ta

Last year

In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Last year
Pharma

Biden awards $24M to de­vel­op mR­NA tech tar­get­ing can­cer, oth­er dis­eases

Last year
Pharma
FDA+

J&J to close its Lei­den vac­cine unit fol­low­ing wider in­fec­tious dis­ease cuts

Last year

Agenus to trim its staff num­bers and as­sets

Last year
People

Pfiz­er ex­pects few­er peo­ple need­ed for Ly­me dis­ease vac­cine tri­al

Last year
Pharma

Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Last year

Ex­clu­sive: As­traZeneca and Vaxess de­vel­op­ing skin patch mR­NA vac­cines for pan­dem­ic flu

Last year
Deals

Apel­lis' safe­ty probe in­to eye drug un­earths is­sues with in­jec­tion kits, while side ef­fects re­main 'very rare'

Last year
Pharma

Ful­crum’s sick­le cell hold re­solved, and tri­al will now fo­cus on more se­vere pa­tients

Last year
FDA+

La­va Ther­a­peu­tics makes cuts to its head­count

Last year
People

In­ovio spin­out plans piv­otal study for can­cer vac­cine as it touts al­ter­na­tive take on PhIb/IIa liv­er can­cer da­ta

Last year

Ar­a­vive warns of pos­si­ble liq­ui­da­tion as it ax­es all clin­i­cal work, lays off 70% of em­ploy­ees

Last year
People

Leo Phar­ma spend­ing $14M up­front to ac­quire Tim­ber

Last year
Deals

FDA puts par­tial hold on Gilead’s CD47 hope­ful in AML

Last year
FDA+
First page Previous page 71727374757677 Next page Last page
A service from the Financial Times